CU6 clarity pharmaceuticals ltd

Ann: Last patient assessment completed for SARTATE trial, page-3

  1. 150 Posts.
    lightbulb Created with Sketch. 203
    Another great announcement. Another product with the potential to be best-in-class.

    Some very encouraging comments by AT. The comments certainly would suggest that there is an unmet medical need...which possibly opens up this product to expedited programs through the FDA (whether that happens or not - I guess we will find out).

    He also goes to great length to explain the benefits of the longer half-life in imaging. He even asserts that issues with tumour-to-background ratio are not overcome with by the state of the art PET scanners with their increased sensitivity.

    I guess we will learn more in the first half of 2025 when the final results from DISCO are released.


 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$4.11
Change
-0.200(4.64%)
Mkt cap ! $1.329B
Open High Low Value Volume
$4.20 $4.27 $4.09 $7.447M 1.792M

Buyers (Bids)

No. Vol. Price($)
1 1000 $4.11
 

Sellers (Offers)

Price($) Vol. No.
$4.12 2000 1
View Market Depth
Last trade - 16.10pm 25/07/2025 (20 minute delay) ?
CU6 (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.